This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities. © 2025 4D Molecular Therapeutics. All Rights Reserved. 2 Bank of America 2025 Healthcare Conference Corporate Presentation May 2025 © 2025 4D Molecular Therapeutics. All Rights Reserved. © 2025 4D Molecular Therapeutics. All Rights Reserved. Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of h ...

Summary of 4D Molecular Therapeutics (FDMT) Conference Call Company Overview - **Company**: 4D Molecular Therapeutics (FDMT) - **Lead Product**: 4150, currently in phase three development for wet age-related macular degeneration (AMD) and diabetic macular edema (DME) [2][3] Industry Context - **Market Size**: The anti-VEGF market is valued at $17 billion and is expected to grow significantly due to an aging population [4] - **Competitive Landscape**: The market is competitive with existing therapies like aflibercept and new entrants like Babizmo, which has shown rapid uptake due to improved durability [4][5] Core Product Insights - **Durability**: 4150 aims to provide multi-year durability compared to existing therapies that offer only a few months of effectiveness [5][6] - **Injection Burden**: Current therapies require 8-10 injections per year, while 4150 could reduce this burden by 83-94% in various patient populations [7][8] - **Safety Profile**: The product has shown a favorable safety profile with no serious adverse events reported, and a low rate of mild transient effects [8][11] Clinical Development - **Phase Three Trials**: Top-line data for wet AMD pivotal trials is expected in the second half of 2027, designed to demonstrate non-inferiority in best corrected visual acuity (BCVA) and significant reduction in injection burden [12][20] - **Regulatory Designation**: 4150 has received RMAT designation for both wet AMD and DME, indicating a favorable regulatory outlook [3][16] Manufacturing and Commercialization - **Manufacturing Strategy**: Currently in-house manufacturing with plans to outsource as commercialization approaches, minimizing exposure to potential tariffs [19] - **Cost of Goods**: Estimated at $500, providing pricing flexibility and potential for favorable payer negotiations [11] Market Expectations and Physician Insights - **Initial Uptake**: Anticipated initial use in patients with high treatment burdens (8-10 injections/year), with gradual adoption in less severe cases as physician familiarity increases [29][30] - **Physician Feedback**: Physicians prioritize significant reductions in injection frequency over complete injection freedom, viewing an 80-90% reduction as a substantial benefit [22][24] Competitive Positioning - **Differentiation**: 4150 aims to set a new standard in durability, potentially offering years of effectiveness compared to competitors that may only extend treatment intervals by a few months [27][28] Additional Programs - **Other Developments**: Active program for 4710 targeting cystic fibrosis lung disease, with promising clinical activity expected to be updated later this year [13] Conclusion - 4D Molecular Therapeutics is positioned to disrupt the retinal vascular disease market with its innovative gene therapy, 4150, which promises significant improvements in treatment durability and patient outcomes while maintaining a strong safety profile. The company is on track for pivotal trial data and is strategically planning for commercialization amidst a competitive landscape.

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.38%. A quarter ago, it was expected that this company would post a loss of $0.80 per share when it actually produced a loss of $0.90, delivering a surprise of -12.50%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Washington, D.C. 20549 Commission File Number 001-39782 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 47-3506994 (State or other ...

Exhibit 99.1 EMERYVILLE, Calif., May 8, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2025 financial results, provided operational highlights and outlined expected upcoming milestones. 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights an ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD$458 million in cash, cash equivalents, and marketable securities as of March 31, 2025 ...

EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). “This ...

EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted ...

EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (wet AM ...

Financial Performance - The company reported net losses of $160.9 million and $100.8 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $576.2 million as of December 31, 2024[161]. - The company anticipates that its future net losses will depend on the level of future expenditures and its ability to generate revenue[162]. - The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it progresses its product candidates through preclinical and clinical development[163]. - The company will require substantial additional capital to finance its operations and may be forced to delay or reduce research and drug development programs if unable to raise such capital[165]. Cash and Assets - As of December 31, 2024, the company had $505.5 million in cash and cash equivalents and marketable securities[166]. Product Development and Clinical Trials - The company has no products approved for commercial sale and has not generated any product revenue to date[160]. - The company has initiated ongoing clinical trials and has additional product candidates in preclinical development[165]. - The company has not completed any clinical trials or obtained marketing approval for any product candidates[160]. - Clinical testing is expensive and time-consuming, with potential delays in clinical trials due to various factors, including regulatory authorization and patient recruitment[197]. - The company plans to initiate Phase 3 studies in 2025 comparing a single dose of 4D-150 to on-label aflibercept, with potential delays posing serious risks to business[197]. - The company faces challenges in patient enrollment for clinical trials due to factors such as disease severity, diagnostic difficulties, and patient access to medical professionals[199]. - Delays in manufacturing and testing processes could hinder the availability of product candidates for clinical trials[200]. - The limited number of patients with rare genetic diseases may complicate the enrollment and completion of clinical trials, impacting statistical significance[205]. - Clinical trials must demonstrate substantial evidence of safety and efficacy, which is essential for regulatory approval and commercialization[218]. - Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization[220]. - The company has limited experience in designing clinical trials, which may hinder marketing approval[221]. Regulatory Challenges - The regulatory approval processes for the company's product candidates are lengthy, expensive, and inherently unpredictable, which could delay commercialization[158]. - The regulatory approval process for novel product candidates can be more expensive and take longer than for extensively studied therapeutic modalities[177]. - The FDA and EMA have established specific committees to review genetic medicine products, which may lengthen the regulatory review process and increase development costs[178][182]. - The company may face significant regulatory oversight, requiring compliance with evolving guidelines that could delay or prevent approval and commercialization[184][183]. - Regulatory approval is uncertain, and the company has never submitted an application for any product candidate, which poses a significant risk to business[210]. - Changes in regulatory requirements or adverse findings could lead to clinical holds or trial terminations, affecting product development timelines[203]. - The company must ensure compliance with cGMP requirements, which involves significant time, money, and effort in production and quality control[245]. - Regulatory agencies may impose restrictions or withdraw approvals if compliance issues arise, which could significantly harm the company's business[266]. - The company may face challenges in maintaining regulatory compliance amid changing policies and new government regulations[268]. Market and Competition - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may hinder its market position[228]. - Competitors may have significantly greater financial resources and expertise, impacting the company's ability to compete effectively[231]. - The company lacks a sales and marketing infrastructure, which may affect the commercialization of approved products[232]. - The company currently lacks a sales organization, which may hinder its ability to effectively market and sell products if approved[298]. - Establishing a sales organization is expected to be expensive and time-consuming, with significant risks involved in hiring and retaining qualified personnel[298]. Intellectual Property - The company has three granted patents and three pending patent applications, with potential government rights affecting their commercialization[318][319]. - The patent application process is uncertain, with risks including non-issuance of patents and challenges from competitors[321]. - The company may not be able to adequately protect its intellectual property, which could harm its competitive position[319][328]. - The lifespan of patents is limited, generally expiring 20 years after the first filing date, which may expose the company to competition[329]. - The company may face difficulties in enforcing patent rights, which could lead to significant expenses and management distraction[324][325]. - The company relies on exclusive license agreements with U.C. Berkeley and the University of Pennsylvania for critical intellectual property related to its product candidates, which may not provide adequate rights for all relevant fields or territories[343]. - The company may not be able to protect its intellectual property rights globally due to high costs and varying levels of protection in different jurisdictions[334]. - The company may face claims challenging the inventorship or ownership of its patents, which could result in costly litigation and loss of valuable intellectual property rights[337]. Collaborations and Third-Party Risks - The company relies on third parties for clinical trials and research, which may affect control over these activities and introduce risks if those parties do not perform satisfactorily[309][310]. - Collaborations with third parties for research and commercialization may limit the company's control and expose it to risks related to intellectual property and resource allocation[313][314]. - The company may incur additional losses and delays in product development if third-party manufacturers or distributors fail to perform as expected[312]. - The negotiation process for collaborations is complex and time-consuming, potentially requiring additional capital if collaborations are not established[316]. - Collaborators may not maintain or defend intellectual property rights effectively, leading to potential litigation and resource diversion[354]. Regulatory Designations and Incentives - The company has received Fast Track designation for 4D-310 for the treatment of Fabry disease, which may allow for more frequent interactions with the FDA during product development[269]. - The company has obtained orphan drug designation for 4D-710 for cystic fibrosis and for 4D-310 for Fabry disease, which may provide market exclusivity and financial incentives[270]. - The FDA may grant orphan drug exclusivity for a product if it is the first to receive approval for a specific disease, providing seven years of protection from competition[272]. - The company has received Regenerative Medicine Advanced Therapy (RMAT) and PRIority MEdicine (PRIME) designations for 4D-150 for the treatment of wet AMD, which may facilitate expedited regulatory review[274]. - The company has obtained a rare pediatric disease designation for 4D-710, which may qualify for a priority review voucher upon FDA approval[280]. Economic and Legislative Factors - Legislative changes, such as the Inflation Reduction Act of 2022, may impose price negotiations and rebates, affecting revenue potential[287]. - The ACA and subsequent legislation have led to reductions in Medicare payments, impacting the financial landscape for pharmaceutical companies[286]. - Increased scrutiny over drug pricing and reimbursement policies may pressure product pricing and demand[289]. - Future healthcare reforms may limit government payments for healthcare products, leading to reduced demand and pricing pressures[288].